Recent Analysts’ Ratings Changes for Fresenius Medical Care AG & Co. KGaA (FMS)

Several brokerages have updated their recommendations and price targets on shares of Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) in the last few weeks:

• 10/15/2026 – Fresenius Medical Care AG & Co. KGaA was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/12/2026 – Fresenius Medical Care AG & Co. KGaA had its price target lowered by Truist Financial Corporation from $25.00 to $24.00. They now have a “hold” rating on the stock.
• 10/8/2026 – Fresenius Medical Care AG & Co. KGaA was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 9/29/2026 – Fresenius Medical Care AG & Co. KGaA was given a new $24.00 price target by Berenberg Bank.
• 9/29/2026 – Fresenius Medical Care AG & Co. KGaA was downgraded by Berenberg Bank from “buy” to “hold”.

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.